Turning Point Therapeutics, Inc. Common Stock
TPTX
TPTX was delisted on the 16th of August, 2022.
120 hedge funds and large institutions have $1.76B invested in Turning Point Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 45 increasing their positions, 21 reducing their positions, and 21 closing their positions.
114% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 21
105% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 21
95% more capital invested
Capital invested by funds: $900M → $1.76B (+$856M)
22% more funds holding
Funds holding: 98 → 120 (+22)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $230K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$67.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$59.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$59.1M |
| 4 |
State Street
Boston,
Massachusetts
|
+$31.3M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$17.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$68.7M |
| 2 |
VP
venBio Partners
San Francisco,
California
|
-$30.1M |
| 3 |
Alkeon Capital Management
New York
|
-$9.52M |
| 4 |
Millennium Management
New York
|
-$9.21M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$8.36M |
TPTX Hedge Fund Activity: Q4 2019 in Review
120 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Turning Point Therapeutics, Inc. Common Stock (TPTX) for Q4 2019, worth a combined $1.76B — up 95% from $900M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new TPTX positions and 21 closed out — a net gain of 22 holders — while 45 added to existing stakes and 21 trimmed.
The largest buyer was BlackRock, adding an estimated $67.3M. The largest seller was Foresite Capital Management IV, exiting entirely with an estimated $68.7M sold.
- 120 institutional investors held Turning Point Therapeutics, Inc. Common Stock (TPTX) as of Q4 2019, up from 98 in Q3 2019.
- Funds reported $1.76B of Turning Point Therapeutics, Inc. Common Stock stock for Q4 2019, up 95% quarter-over-quarter.
- 43 funds opened new Turning Point Therapeutics, Inc. Common Stock positions in Q4 2019 and 21 closed out, a net change of +22 holders.
- The largest Turning Point Therapeutics, Inc. Common Stock buyer in Q4 2019 was BlackRock, an estimated $67.3M added.
- The largest Turning Point Therapeutics, Inc. Common Stock seller in Q4 2019 was Foresite Capital Management IV, an estimated $68.7M sold.
Based on aggregated 13F filings for Q4 2019.